E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with metastacic breast cancer disease and anemia |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
to compare response to treatment and time to disease progression in patients with metastatic breast cancer, which have detected Hb levels ≤110g/l and are treated with capecetabine/docetaxel with or without epoetin beta. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Form of informed individual consent signed prior to applying any specific trial selection procedure 2. Patients willing and capable to follow the requirements indicated in the protocol 3. Patients older than 18 years 4. Histologically confirmed metastatic breast carcinoma 5. Patients having no contraindications against capecitabine/docetaxsel treatment 6. Hb ≤ 110g/l 7. Grade according to ECOG Performance Status: 0-2 8. Estimated term of life ≥ 6 months 9. Agreement of pre-menopausal patients to use contraceptives during the trial terms
|
|
E.4 | Principal exclusion criteria |
1. Other malignant tumours during the last 5 years (other than completely treated basal cells and (or) squamous cell skin carcinoma (or) squamous cell skin carcinoma and (or) cervical in situ carcinoma) 2. Pregnancy (positive serum pregnancy test) and breast feeding 3. Earlier or detected during inspection disease of CNS (e.g., primary brain tumour, seizures not controllable by standard drug medication, any brain metastases) 4. Clinically significant heart disease, not controllable by drug medication: 4.1. Heart insufficiency, symptomatic coronary heart disease or heart arrhythmia (NYHA class 3 or 4, see. Appendix III) 4.2. Myocardial infarction during the last 12 months 4.3. Treatment resistant hypertension 5. Peripheral neuropathy ≥ 1 grade 6. Transfusion of erythrocyte mass during the last month prior to involvement into clinical trial 7. Anaemia not related directly to chemotherapy and (or) tumour itself 7.1. Iron deficiency anaemia (Fe < LLN or feritine <10 µg/l), which can not be corrected with iron supplements 7.2. Vitamin B12 deficiency anaemia (MCV >105 fL and/or vitamin B12 concentration < LLN), which can not be corrected with vitamin B12 7.3. Folic acid deficiency anaemia (MCV >105 fL and/or folic acid concentration < LLN), which can not be corrected with folic acid preparations 7.4. Haemolytic anaemia (laboratory indications of haemolysis: reticulocytes > ULN and indirect bilirubine >ULN ± LDH > ULN) 8. Any laboratory indication value as given below: 8.1. General blood test: number of neutrophils < 1,5 x 109/l, number of thrombocites < 50 x 109/l, 8.2. Biochemical blood test: total bilirubine > 1,5 x upper norm limit (ULN), ASAT, ALT > 2,5 x ULN, alkaline phosphatase > 2,5 x ULN, serum creatinine > 1,5 x ULN or creatinine clearance ≤ 50 ml/min (calculated according to Cockroft and Gault formula or formula presented in the internet web page: http://www.globalrph.com/crcl.htm) 9. Present or recent (28 days prior to randomisation) uptake of another trial drug or participation in another clinical trial 10. Thrombophylia detected by anamnesis and/or clinically confirmed deep venous thrombosis 11. Acute or chronic bleeding requiring treatment during the last month
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- objective response to treatment, based on tumor evaluation by criteria. Response to treatment is considered like partial remission (PR), complete remission, stable disease (SD), progressive disease (PD); - time to disease progression |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |